Listen to this Article Now
Getting your Trinity Audio player ready...
The Medicines and Healthcare products Regulatory Agency of the United Kingdom has approved Pfizer’s Paxlovid oral antiviral for people with mild to moderate COVID-19 who have at least one risk factor for developing severe illness.
Merck’s Lagevrio was approved by the FDA last month. The FDA stated that it is too early to tell whether the omicron variant has any effect on Paxlovid’s efficacy. “We now have another antiviral medication for the treatment of COVID-19 that can be taken orally rather than intravenously. This means that it can be given outside of a hospital setting before COVID-19 has progressed to a severe stage “Dr. June Raine, the MHRA’s chief executive, stated Market Pulse Stories are quick news bursts about stocks and markets as they move.